dr. mok on dacomitinib for first-line lung cancer treatment
Published 5 years ago • 918 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
1:53
dr. mok on the utility of afatinib in lung cancer
-
1:18
dr. mok on breakthrough therapies for alk-positive nsclc
-
1:02
dr. mok on overall survival data from the alex trial in alk lung cancer
-
0:49
dr. mok on plasma testing in lung cancer
-
0:52
dr. shum discusses dacomitinib in egfr nsclc
-
1:36
dr. mark kris discusses dacomitinib for patient with egfr-positive lung cancer
-
1:21
dr. bertino on frontline dacomitinib in metastatic egfr nsclc
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
1:03
dr. wakelee discusses dacomitinib in egfr nsclc
-
1:01
dr. heymach on nivolumab for lung cancer
-
0:58
dr. papadimitrakopoulou on treatment options for egfr-mutant nsclc
-
1:38
dr. mok discusses next steps for pembrolizumab in nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:14
dr. halmos on second-line treatment in metastatic squamous nsclc
-
1:19
dr. dimou on managing disease progression in nsclc
-
2:02
dr. dimou on progress made in alk lung cancer treatment